Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group

被引：5

作者：

Fazio, Francesca ^{[1
]}

Franceschini, Luca ^{[2
]}

Tomarchio, Valeria ^{[3
]}

Rago, Angela ^{[4
]}

Garzia, Maria Grazia ^{[5
]}

Cupelli, Luca ^{[6
]}

Bongarzoni, Velia ^{[7
]}

Andriani, Alessandro ^{[8
]}

Gumenyuk, Svitlana ^{[9
]}

Tafuri, Agostino ^{[10
]}

Siniscalchi, Agostina ^{[11
]}

Piciocchi, Alfonso ^{[12
]}

De Fabritiis, Paolo ^{[13
]}

De Rosa, Luca ^{[14
]}

di Toritto, Tommaso Caravita ^{[15
]}

Annibali, Ombretta ^{[16
]}

Cantonetti, Maria ^{[17
]}

Petrucci, Maria Teresa ^{[1
]}

机构：

[1] Sapienza Univ Rome, Dept Translat & Precis Med Hematol, Azienda Policlin Umberto 1, Rome, Italy

[2] Transplant Network, Hematol Stem Cell Transplant Unit, Rome, Italy

[3] Univ Campus Biomed, Dept Haematol, Rome, Italy

[4] ASL RMA, UOSD Ematologia Asl Roma 1, Rome, Italy

[5] San Camillo Forlanini Hosp, Dept Hematol, Hematol, Rome, Italy

[6] Osped St Eugenio, Hematol, Dept Hematol, Rome, Italy

[7] San Giovanni Addolorata Hosp, Dept Hematol, Rome, Italy

[8] Osped Fabrizio Spaziani, Dept Hematol, Rome, Italy

[9] Regina Elena Inst Canc Res, Haematol & Stem Cell Transplant, Rome, Italy

[10] Azienda Osped St Andrea, Rome, Italy

[11] S Eugenio Hosp, Inst Haematol, Rome, Italy

[12] Italian Grp Adult Hematol Dis GIMEMA, Ctr Data, Rome, Italy

[13] Osped St Eugenio, Dept Haematol, Rome, Italy

[14] Azienda Osped San Camillo Forlanini, Hematol & Bone Marrow Transplantat Unit, Rome, Italy

[15] ASL Roma 1, Dept Hematol, Rome, Italy

[16] Campus Biomed Univ Rome, Dept Haematol, Rome, Italy

[17] Univ Tor Vergata, Chair Hematol, Rome, Italy

来源：

EJHAEM | 2022年 / 3卷 / 01期

关键词：

immunotherapy; multiple myeloma; relapsed refractory; PLUS LENALIDOMIDE; MONOTHERAPY; CD38; LYMPHOCYTES; EFFICACY; CELLS;

D O I：

10.1002/jha2.359

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab is a human IgGK monoclonal antibody targeting CD38 with tumor activity associated with immunomodulatory mechanism. In combination with standard of care regimens, including bortezomib (Vd) or lenalidomide (Rd), daratumumab prolonged progression-free survival (PFS) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and in new diagnosis MM. We report the data of the MM GIMEMA Lazio group in 171 heavily treated pts who received daratumumab, lenalidomide and dexamethasone (DRd) or daratumumab, velcade and dexamethasone (DVd). The overall response rate was 80%, and the overall survival (OS) and PFS were 84% and 77%, respectively. In addition, pts treated with DRd showed a better median PFS compared to pts treated with DVd, at 12 and 24 months, respectively. The most common hematologic treatment-emergent adverse events (TAEs) were neutropenia, thrombocytopenia, and anemia. The most common nonhematologic TAEs were peripheral sensory neuropathy and infections. Our data confirmed that DRd or DVd therapy is effective and safe in RRMM pts, and our real-life analysis could support the physicians regarding the choice of optimal therapy in this setting of pts.

引用

页码：121 / 128

页数：8

共 32 条

[1] Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience [J].

Antonioli, Elisabetta ;

Staderini, Michela ;

Pilerci, Sofia ;

Perfetto, Federico ;

Cappelli, Francesco ;

Allinovi, Marco ;

Nozzoli, Chiara ;

Attucci, Irene ;

Buzzichelli, Alessandra ;

Messeri, Maria ;

Bosi, Alberto .

LEUKEMIA & LYMPHOMA, 2020, 61 (13) :3255-3258

[2] Secretion of IFN-gamma, IL-6, granulocyte-macrophage colony-stimulating factor and IL-10 cytokines after activation of human purified T lymphocytes upon CD38 ligation [J].

Ausiello, CM ;

laSala, A ;

Ramoni, C ;

Urbani, F ;

Funaro, A ;

Malavasi, F .

CELLULAR IMMUNOLOGY, 1996, 173 (02) :192-197

[3] Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma [J].

Bonello, Francesca ;

Mina, Roberto ;

Boccadoro, Mario ;

Gay, Francesca .

CANCERS, 2020, 12 (01)

[4] Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience [J].

Byun, Ja Min ;

Yoon, Sung-Soo ;

Koh, Youngil ;

Kim, Inho ;

Jo, Jaemin ;

Park, Hyunkyung ;

Lee, Jeong-Ok ;

Lee, Jiyun .

ANTICANCER RESEARCH, 2019, 39 (09) :5165-5170

[5] Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity [J].

Cagnetta, Antonia ;

Cea, Michele ;

Calimeri, Teresa ;

Acharya, Chirag ;

Fulciniti, Mariateresa ;

Tai, Yu-Tzu ;

Hideshima, Teru ;

Chauhan, Dharminder ;

Zhong, Mike Y. ;

Patrone, Franco ;

Nencioni, Alessio ;

Gobbi, Marco ;

Richardson, Paul ;

Munshi, Nikhil ;

Anderson, Kenneth C. .

BLOOD, 2013, 122 (07) :1243-1255

[6] Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors [J].

de Weers, Michel ;

Tai, Yu-Tzu ;

van der Veer, Michael S. ;

Bakker, Joost M. ;

Vink, Tom ;

Jacobs, Danielle C. H. ;

Oomen, Lukas A. ;

Peipp, Matthias ;

Valerius, Thomas ;

Slootstra, Jerry W. ;

Mutis, Tuna ;

Bleeker, Wim K. ;

Anderson, Kenneth C. ;

Lokhorst, Henk M. ;

van de Winkel, Jan G. J. ;

Parren, Paul W. H. I. .

JOURNAL OF IMMUNOLOGY, 2011, 186 (03) :1840-1848

[7] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].

Dimopoulos, M. A. ;

Oriol, A. ;

Nahi, H. ;

San-Miguel, J. ;

Bahlis, N. J. ;

Usmani, S. Z. ;

Rabin, N. ;

Orlowski, R. Z. ;

Komarnicki, M. ;

Suzuki, K. ;

Plesner, T. ;

Yoon, S. -S. ;

Ben Yehuda, D. ;

Richardson, P. G. ;

Goldschmidt, H. ;

Reece, D. ;

Lisby, S. ;

Khokhar, N. Z. ;

O'Rourke, L. ;

Chiu, C. ;

Qin, X. ;

Guckert, M. ;

Ahmadi, T. ;

Moreau, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) :1319-1331

[8] Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma [J].

Facon, T. ;

Kumar, S. ;

Plesner, T. ;

Orlowski, R. Z. ;

Moreau, P. ;

Bahlis, N. ;

Basu, S. ;

Nahi, H. ;

Hulin, C. ;

Quach, H. ;

Goldschmidt, H. ;

O'Dwyer, M. ;

Perrot, A. ;

Venner, C. P. ;

Weisel, K. ;

Mace, J. R. ;

Raje, N. ;

Attal, M. ;

Tiab, M. ;

Macro, M. ;

Frenzel, L. ;

Leleu, X. ;

Ahmadi, T. ;

Chiu, C. ;

Wang, J. ;

Van Rampelbergh, R. ;

Uhlar, C. M. ;

Kobos, R. ;

Qi, M. ;

Usmani, S. Z. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22) :2104-2115

[9] Immunotherapy in myeloma: how far have we come? [J].

Franssen, Laurens E. ;

Mutis, Tuna ;

Lokhorst, Henk M. ;

van de Donk, Niels W. C. J. .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10 :1-19

[10] The REDCap consortium: Building an international community of software platform partners [J].

Harris, Paul A. ;

Taylor, Robert ;

Minor, Brenda L. ;

Elliott, Veida ;

Fernandez, Michelle ;

O'Neal, Lindsay ;

McLeod, Laura ;

Delacqua, Giovanni ;

Delacqua, Francesco ;

Kirby, Jacqueline ;

Duda, Stephany N. .

JOURNAL OF BIOMEDICAL INFORMATICS, 2019, 95

← 1 2 3 4 →